Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Updates in amyloidosis: ISA 2020

Joan Bladé • 17 May 2019
COMy 2019
Amyloidosis Rare Diseases Bortezomib Cyclophosphamide Daratumumab Dexamethasone Ixazomib

Joan Bladé, MD, PhD, of Hospital Clinic, Barcelona, Spain, briefly describes new agents used in the treatment of relapsed amyloidosis, including daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd). Additionally, Dr Bladé discusses the upcoming International Symposium on Amyloidosis (ISA) in March 2020, to be held in Tarragona, Spain, of which Dr Bladé will be President. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Joan Bladé

2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
3:05
Amyloidosis classification and epidemiology
Joan Bladé • 4 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals